Co-encapsulation of curcumin and doxorubicin in albumin nanoparticles blocks the adaptive treatment tolerance of cancer cells

• DOI: 10.1007/s41048-018-0079-6
• Publication Date: 2019-01-11T00:15:00Z
• Authors: Seyed Mohammad Mo...; Ahmed Shaker Eltahan; Lu Liu; Andrea Magrini; Nicola Rosato; Weisheng Guo; Massimo Bottini; Xing-Jie Liang
• Keywords: 0301 basic medicine; 03 medical and health sciences; 3. Good health

The adaptive treatment tolerance (ATT) of cancer cells is the main encumbrance to chemotherapy. A potential solution this problem treat with multiple drugs using nanoparticles (NPs). In study, we tested co-administration curcumin (Cur) and doxorubicin (Dox) MCF-7 resistant breast block ATT elicit efficient cell killing. Drugs were co-administered both sequentially simultaneously. Sequential drug was carried out by pre-treating albumin (ANPs) loaded Cur (Cur@ANPs) followed Dox-loaded ANPs (Dox@ANPs). Simultaneous treating (Cur/Dox@ANPs). We found that simultaneous led a greater intra-cellular accumulation Dox killing respect sequential co-administration. However, lower showed result due aggregation entrapment in lysosomes as soon it released from Cur@ANPs, phenomenon called lysosomotropism. contrast, release Cur/Dox@ANPs into lysosomal pH elevation, which, turn, avoided aggregation, lysosome swelling cytosol, finally provoked Our study shed light on molecular processes driving therapeutic effects anti-cancer different manners.